| Bioactivity | CFG920 is an orally active, nonsteroidal, reversible dual CYP17 and CYP11B2 inhibitor. CFG920 has the potential for metastatic castration-resistant prostate cancer research[1][2]. |
| CAS | 1260006-20-9 |
| Formula | C14H13ClN4O |
| Molar Mass | 288.73 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Chris Lu, et al. Method of treating cancer. WO2021026454A1. [2]. https://patents.google.com/patent/WO2021026454A1/en?oq=WO2021026454 |